These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 8677446

  • 1. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
    Vose JM.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
    [Abstract] [Full Text] [Related]

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 3. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 4. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [Abstract] [Full Text] [Related]

  • 5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 6. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY, Boros L, Garrow GC, Asbury RF, Hui L.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [Abstract] [Full Text] [Related]

  • 7. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [Abstract] [Full Text] [Related]

  • 8. Ifosfamide in the treatment of non-Hodgkin's lymphoma.
    Pohlman B.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):27-32. PubMed ID: 8677445
    [Abstract] [Full Text] [Related]

  • 9. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH.
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E.
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F.
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [Abstract] [Full Text] [Related]

  • 12. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
    Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL.
    Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
    [Abstract] [Full Text] [Related]

  • 13. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):533-41. PubMed ID: 18398095
    [Abstract] [Full Text] [Related]

  • 14. Ifosfamide in the treatment of lymphoma.
    Coiffier B.
    Semin Oncol; 1996 Jun 16; 23(3 Suppl 7):2-7. PubMed ID: 8711498
    [Abstract] [Full Text] [Related]

  • 15. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A, Ueoka H, Kiura K, Tabata M, Sunami K, Katayama Y, Yamane H, Hiraki A, Harada M.
    Anticancer Res; 1999 Jun 16; 19(1B):693-8. PubMed ID: 10216478
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide in the treatment of germ cell tumors.
    Nichols CR.
    Semin Oncol; 1996 Jun 16; 23(3 Suppl 6):65-73. PubMed ID: 8677452
    [Abstract] [Full Text] [Related]

  • 17. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4083-91. PubMed ID: 14568987
    [Abstract] [Full Text] [Related]

  • 18. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M, Yoshizawa H, Tanaka H, Tanaka J, Kagamu H, Ito K, Shimbo T, Chou D, Wakabayashi M, Suzuki E, Sakai K, Arakawa M, Gejyo F.
    Bone Marrow Transplant; 2000 Jan 15; 25(1):5-11. PubMed ID: 10654007
    [Abstract] [Full Text] [Related]

  • 19. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
    Haematologica; 2002 Aug 15; 87(8):816-21. PubMed ID: 12161357
    [Abstract] [Full Text] [Related]

  • 20. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.
    Caracciolo D, Gavarotti P, Aglietta M, Bondesan P, Falda M, Gallo E, Locatelli F, Novarino A, Paolino F, Sanavio F.
    Bone Marrow Transplant; 1993 Dec 15; 12(6):621-5. PubMed ID: 7907906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.